Pharma-Bio Serv (PBSV) Cash & Current Investments (2010 - 2026)

Pharma-Bio Serv has reported Cash & Current Investments for 17 years, with the latest figure at $10.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 15.07% year-over-year to $10.6 million; the trailing twelve-month figure through Jan 2026 stood at $10.6 million (down 15.07% YoY), and the FY2025 full-year result was $10.9 million, down 14.84% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $10.6 million, down from $10.9 million in the prior quarter.
• The five-year high for Cash & Current Investments was $15.9 million in Q1 2024, with the low at $10.4 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $13.3 million across 5 years, with a median of $13.5 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Current Investments gained 3.56% — and 2025, when it declined 22.75%.
• Pharma-Bio Serv's Cash & Current Investments stood at $14.5 million in 2022, then climbed by 3.56% to $15.0 million in 2023, then retreated by 14.9% to $12.7 million in 2024, then decreased by 14.84% to $10.9 million in 2025, then retreated by 2.71% to $10.6 million in 2026.
• The last three Cash & Current Investments figures came in at $10.6 million (Q1 2026), $10.9 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.